Non-small cell lung cancer
Conditions
Interventions
Experimental group:Atezolizumab (1200mg, IV, D1) in combination with investigator-selected chemotherapy (docetaxel/white purple ± platinum), administered every 3 weeks as a treatment cycle.
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed IIIb-IV stage non-small cell lung cancer; 2. Disease progression or intolerance after prior treatment with immune checkpoint inhibitors such as PD-1, PD-L1, or CTLA-4; 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2; 4. Age >= 18 years and = 12 weeks; 8. Adequate organ and bone marrow function before receiving study treatment; 9. Participants voluntarily join the study, sign an informed consent form, and have good adherence.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors within 5 years prior to enrollment, as well as those with a history of skin basal cell or squamous cell carcinoma or cervical carcinoma in situ after curative surgery, are excluded. Subjects who are found to have a second primary malignant tumor at the time of enrollment; 2. Patients receiving other antitumor drug treatments concurrently during the treatment period of this study protocol; 3. Any clinical or laboratory abnormalities or noncompliance that the investigator deems unsuitable for participation in this clinical trial; 4. Severe liver or kidney dysfunction or contraindications for immune checkpoint inhibitors before receiving this study protocol; 5. The presence of other acute or chronic diseases, psychiatric disorders, or abnormal laboratory test values prior to receiving this study protocol, that may lead to increased risk related to study participation or drug administration, or that may interfere with the interpretation of study results, and the investigator determines that the subject is not eligible to participate; 6. Subjects who have previously discontinued treatment due to adverse reactions caused by immune checkpoint inhibitors; 7. Other subjects deemed ineligible for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate;Objective response rate; | — |
Countries
China
Contacts
Public ContactGuozheng Ding
Anqing Municipal Hospital
Outcome results
None listed